Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)

Annalisa Aratari, Fabrizio Bossa, Maria Cappello, Andrea Cassinotti, Alberto Chiriatti, Gionata Fiorino, Vincenzo Formica, Luisa Guidi, Alessandra Losco, Filippo Mocciaro, Sara Onali, Luca Pastorelli, Roberta Pica, Mariabeatrice Principi, Sara Renna, Chiara Ricci, Antonio Rispo, Francesca Rogai, Loredana Sarmati, Franco ScaldaferriLuisa Spina, Rosy Tambasco, Anna Testa, Angelo Viscido, Livia Biancone, Vito Annese, Sandro Ardizzone, Alessandro Armuzzi, Emma Calabrese, Flavio Caprioli, Fabiana Castiglione, Michele Comberlato, Mario Cottone, Silvio Danese, Marco Daperno, Renata D'Incà, Giuseppe Frieri, Walter Fries, Paolo Gionchetti, Anna Kohn, Giovanni Latella, Monica Milla, Ambrogio Orlando, Claudio Papi, Carmelina Petruzziello, Gabriele Riegler, Fernando Rizzello, Simone Saibeni, Maria Lia Scribano, Maurizio Vecchi, Piero Vernia, Gianmichele Meucci, Massimo Rugge

Research output: Contribution to journalArticlepeer-review

Abstract

Inflammatory bowel diseases are chronic conditions of unknown etiology, showing a growing incidence and prevalence in several countries, including Italy. Although the etiology of Crohn's disease and ulcerative colitis is unknown, due to the current knowledge regarding their pathogenesis, effective treatment strategies have been developed. Several guidelines are available regarding the efficacy and safety of available drug treatments for inflammatory bowel diseases. Nevertheless, national guidelines provide additional information adapted to local feasibility, costs and legal issues related to the use of the same drugs. These observations prompted the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) to establish Italian guidelines on the safety of currently available treatments for Crohn's disease and ulcerative colitis. These guidelines discuss the use of aminosalicylates, systemic and low bioavailability corticosteroids, antibiotics (metronidazole, ciprofloxacin, rifaximin), thiopurines, methotrexate, cyclosporine A, TNFα antagonists, vedolizumab, and combination therapies. These guidelines are based on current knowledge derived from evidence-based medicine coupled with clinical experience of a national working group.

Original languageEnglish
Pages (from-to)338-358
Number of pages21
JournalDigestive and Liver Disease
Volume49
Issue number4
DOIs
Publication statusPublished - Apr 1 2017

Keywords

  • Guidelines
  • Inflammatory bowel disease
  • Medical treatments
  • Safety

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)'. Together they form a unique fingerprint.

Cite this